Medullary Thyroid Carcinoma: a 25-Year Perspective

被引:27
|
作者
Matias-Guiu, Xavier [1 ,2 ]
De Lellis, Ronald [3 ,4 ]
机构
[1] Univ Lleida IRBLLEIDA, Hosp Univ Arnau Vilanova, Dept Pathol, Lleida 25198, Spain
[2] Univ Lleida IRBLLEIDA, Hosp Univ Arnau Vilanova, Mol Genet & Res Lab, Lleida 25198, Spain
[3] Brown Univ, Warren Alpert Med Sch, Dept Pathol & Lab Med, Providence, RI 02912 USA
[4] Rhode Isl & Miriam Hosp, Providence, RI USA
关键词
Medullary thyroid carcinoma; RET; Pathology; Immunohistochemistry; Molecular pathology; Targeted therapy; MULTIPLE ENDOCRINE NEOPLASIA; C-CELL HYPERPLASIA; RET PROTOONCOGENE; TRANSGENIC MICE; PROGNOSTIC-FACTORS; GENETIC MODIFIERS; 2A MUTATION; MEN; 2A; GLAND; MICROCARCINOMA;
D O I
10.1007/s12022-013-9287-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article summarizes the major clinical, pathological, and molecular features of medullary thyroid carcinoma (MTC), based on a review of the most significant advances in our understanding of this tumor type over the last 25 years. MTC is a neuroendocrine carcinoma that shows evidence of C-cell differentiation. The tumor has a distinctive morphologic appearance, including the presence of amyloid deposits. Immunostaining for calcitonin, carcinoembryonic antigen, calcitonin gene-related peptide, and thyroid transcription factor 1 is helpful in differential diagnosis. Identification of RET mutations in familial and sporadic MTC has brought important changes in early diagnosis and treatment. Surgery remains the cornerstone of effective therapy. Understanding the molecular basis of MTC will allow identification of novel approaches for individualized treatment.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [1] Medullary Thyroid Carcinoma: a 25-Year Perspective
    Xavier Matias-Guiu
    Ronald De Lellis
    Endocrine Pathology, 2014, 25 : 21 - 29
  • [2] Carcinoma of the thyroid in children: A 25-year experience
    Sykes, AJ
    Gattamaneni, HR
    MEDICAL AND PEDIATRIC ONCOLOGY, 1997, 29 (02): : 103 - 107
  • [3] TAMOXIFEN - 25-YEAR PERSPECTIVE
    HIGA, GM
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (03): : 400 - 403
  • [4] THALIDOMIDE - A 25-YEAR PERSPECTIVE
    SHERMAN, M
    STRAUSS, S
    FOOD AND DRUG LAW JOURNAL, 1986, 41 (04): : 458 - 466
  • [5] Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience
    Mohebati, A.
    DiLorenzo, M.
    Palmer, F.
    Patel, S. G.
    Pfister, D.
    Lee, N.
    Tuttle, R. M.
    Shaha, A. R.
    Shah, J. P.
    Ganly, I.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (05) : 1665 - 1670
  • [6] Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience
    A. Mohebati
    M. DiLorenzo
    F. Palmer
    S. G. Patel
    D. Pfister
    N. Lee
    R. M. Tuttle
    A. R. Shaha
    J. P. Shah
    I. Ganly
    Annals of Surgical Oncology, 2014, 21 : 1665 - 1670
  • [7] Critiquing Pygmalion: A 25-year perspective
    Rosenthal, R
    CURRENT DIRECTIONS IN PSYCHOLOGICAL SCIENCE, 1995, 4 (06) : 171 - 172
  • [8] The hyperbolic law - a 25-year perspective
    Stumvoll, M
    Tataranni, PA
    Bogardus, C
    DIABETOLOGIA, 2005, 48 (02) : 207 - 209
  • [9] The insulin story: A 25-year perspective
    Woods, SC
    Nolan, LJ
    APPETITE, 1997, 28 (03) : 281 - 282
  • [10] The hyperbolic law—a 25-year perspective
    M. Stumvoll
    P. A. Tataranni
    C. Bogardus
    Diabetologia, 2005, 48 : 207 - 209